Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes

Kim, Kun-Soo; Lee, Y K; Kim, J S; Koo, Kyung Hye; Hong, Hyo Jeong; Park, Yu Shin

doi:10.1038/cgt.2008.11

Cited by 18 publications

(6 citation statements)

References 36 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2), which is consistent with the previous result. 17 The results clearly showed that the HuCC49 Fab' fragments specifically target the antigen TAG-72 present on the surface of the TAG-72-positive colon cancer cells.…”

Section: Resultsmentioning

confidence: 92%

Enhanced Tumor-targeted Gene Delivery by Immunolipoplexes Conjugated with the Humanized Anti-TAG-72 Fab' Fragments

Kim¹,

Park²,

Hong³

et al. 2012

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Cationic immunoliposomes were prepared by conjugation of Fab' fragments of the recombinant humanized monoclonal antibody (HuCC49) against tumor-associated glycoprotein (TAG)-72 to sterically unilamella liposomes. The cationic immunoliposomes are composed of cationic lipid (O,O'-dimyristyl-N-lysyl aspartate, DMKD), cholesterol, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol) 2000 ] (DPPE-PEG-maleimide) with a molar ratio of 0.5:0.47:0.03. Plasmid DNA was effectively condensed by addition of transferrin (Tf) during the formation of anti-TAG-72 PEG-immunolipoplexes (PILPs). These anti-TAG-72 PILPs were able to adhere to the surface of TAG-72-overexepressing LS174T human colon cancer cells more effectively than conventional liposomes, thereby facilitating gene delivery in vitro. Furthermore, intravenous administration of the anti-TAG-72 PILPs into the tumor-carrying mice exhibited efficient localization of the reporter gene in the tumor tissues.

show abstract

Section: Resultsmentioning

confidence: 92%

Enhanced Tumor-targeted Gene Delivery by Immunolipoplexes Conjugated with the Humanized Anti-TAG-72 Fab' Fragments

Kim¹,

Park²,

Hong³

et al. 2012

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

show abstract

“…Another therapeutic strategy with anti-STn antibodies is drug delivery. PEG-immunoliposomes (PILs) were prepared by conjugation of Fab' fragments of huCC49 to target STn-overexpressing cancer cells [217]. These anti-TAG-72 PILs were able to adhere to the surface of TAG-72-overexpressing LS174 T human colon cancer cells more effectively than conventional liposomes.…”

Section: Sialyl-tn Antigenmentioning

confidence: 99%

“…These anti-TAG-72 PILs were able to adhere to the surface of TAG-72-overexpressing LS174 T human colon cancer cells more effectively than conventional liposomes. Intravenous administration of the anti-TAG-72 PILs, containing plasmids encoding antiangiogenic proteins, significantly inhibited in vivo growth of LS174 T tumors and angiogenesis in the tumor tissues [217]. Anti-STn antibody drug conjugate was generated using CC49 and MMAE, an antimitotic agent that inhibits cell division by blocking the polymerization of tubulin [218].…”

Section: Sialyl-tn Antigenmentioning

confidence: 99%

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

Berois

Pittini

Osinaga

2022

Cancers

View full text Add to dashboard Cite

Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of CAR-T cells. Some approaches have been approved for clinical use, such as anti-GD2 antibodies. Moreover, in terms of the antitumor mechanisms against different TACAs, we show results of selected clinical trials, considering the horizons that have opened up as a result of recent developments in technologies used for cancer control.

show abstract

“…Targeting is essential for the treatment of CRC. The most commonly used biomarkers in CRC include carcinoembryonic antigen (CEA) [112], death receptor 5 (DR5, also known as TRAIL receptor 2) [113], epithelial growth factor receptor (EGFR) [114], tumor-associated glycoprotein (TAG)-72 [115], and folate receptor-α (FRα). The conjugation of ligands on the surface of nanocarriers for the targeted delivery of RNA therapeutics to CRC cells has been widely used.…”

Section: Targeted Nanoparticles For Rna Delivery To Colorectal Cancer Cellsmentioning

confidence: 99%

RNA-based therapeutics for colorectal cancer: Updates and future directions

Liu

Guo

2020

Pharmacological Research

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common causes of cancer death worldwide. While standard chemotherapy and new targeted therapy have been improved recently, problems such as multidrug resistance (MDR) and severe side effects remain unresolved. RNAs are essential to all biological processes including cell proliferation and differentiation, cell cycle, apoptosis, activation of tumor suppressor genes, suppression of oncogenes. Therefore, there are various potential approaches to address genetic disease like CRC at the RNA level. In contrast to conventional treatments, RNA-based therapeutics such as RNA interference, antisense oligonucleotides, RNA aptamer, ribozymes, have the advantages of high specificity, high potency and low toxicity. It has gained more and more attention due to the flexibility in modulating a wide range of targets. Here, we highlight recent advances and clinical studies involving RNA-based therapeutics and CRC. We also discuss their advantages and limitations that remain to be overcome for the treatment of human CRC.

show abstract

Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes

Cited by 18 publications

References 36 publications

Enhanced Tumor-targeted Gene Delivery by Immunolipoplexes Conjugated with the Humanized Anti-TAG-72 Fab' Fragments

Enhanced Tumor-targeted Gene Delivery by Immunolipoplexes Conjugated with the Humanized Anti-TAG-72 Fab' Fragments

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

RNA-based therapeutics for colorectal cancer: Updates and future directions

Contact Info

Product

Resources

About